Plasminogen activator inhibitor-1 secretion by endothelial cells increases fibrinolytic resistance of an in vitro fibrin clot: Evidence for a key role of endothelial cells in thrombolytic resistance

Blood

Volumn 87, Issue 10, 1996, Pages 4204-4213

  Handt, S ^a   Jerome, W G ^b   Tietze, L ^b   Hantgan, R R ^b  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR NECROSIS FACTOR ALPHA;

ACUTE HEART INFARCTION; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD CLOT LYSIS; BLOOD CLOTTING; ENDOTHELIUM CELL; FIBRIN CLOT; FIBRINOLYSIS; HUMAN; HUMAN CELL; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL;

EID: 0029878591     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.10.4204.bloodjournal87104204     Document Type: Article

References (59)

1. Kleiman NS, Terrin M, Mueller H, Chaitman B, Roberts R, Knatterud GL, Solomon R, McMahon RP, Braunwald E, TIMI Investigators: Mechanisms of early death despite thrombolytic therapy: Experience from the Thrombolysis in Myocardial Infarction Phase II (TIMI II) study. J Am Coll Cardiol 19:1129, 1992
2. The GUSTO Investigators: An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329:673, 1993
3. Cannon CP, Antman EM, Walls R, Braunwald E: Time as an adjunctive agent to thrombolytic therapy. J Thromb Thrombolys 1:27, 1994
4. Granger CB, White HD, Bates ER, Ohman EM, Califf RM: A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction. Am J Cardiol 74:1220, 1994
5. 2-antiplasmin to fibrin. Thromb Haemost 68:315, 1992
6. Kunitada S, FitzGerald GA, FitzGerald DJ: Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction. Blood 79:1420, 1992
7. Braaten JV, Handt S, Jerome WG, Kirkpatrick CJ, Lewis JC, Hantgan RR: Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1 (PAI-1): Light scattering and ultrastructural examination of a model platelet-fibrin thrombus. Blood 81:1290, 1993
8. Reilly CF, Hutzelmann JE: Plasminogen activator inhibitor-1 binds to fibrin and inhibits tissue-type plasminogen activator-mediated fibrin dissolution. J Biol Chem 267:17128, 1992
9. Stringer HAR, Swieten PV, Heijnen HFG, Sixma JJ, Pannekoek H: Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Arterioscler Thromb 14:1452, 1994
10. 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis. Thromb Haemost 70:301, 1993
11. Levi M, Biemond BJ, van Zonneveld AJ, ten Cate JW, Pannekoek H: Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 85:305, 1992
12. Biemond BJ, Levi M, Coronel R, Janse MJ, ten Cate JW, Pannekoek H: Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Circulation 91:1175, 1995
13. Booth NA, Robbie LA, Croll AM, Bennett B: Lysis of platelet-rich thrombi: The role of PAI-1. Ann NY Acad Sci 667:70, 1992
14. Loskutoff DJ, Curriden SA: The fibrinolytic system of the vessel wall and its role in thrombosis. Ann NY Acad Sci 598:238, 1990
15. Nachmann RL, Hajjar KA: Endothelial cell fibrinolytic assembly. Ann NY Acad Sci 614:240, 1991
16. Loskutoff DJ, van Aken BE, Seiffert D: Abnormalities in the fibrinolytic system of the vascular wall associated with atherosclerosis. Ann NYAcad Sci 748:177, 1995
17. Raghunath PN, Tomaszewski JE, Brady ST, Caron RJ, Okada SS, Barnathan ES: Plasminogen activator system in human coronary atherosclerosis. Arterioscl Thromb Vasc Biol 15:1432, 1995
18. Lupu F, Bergonzelli GE, Heim DA, Cousin E, Genton CY, Bachmann F, Kruithof EKO: Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arteriosler Thromb 13:1090, 1993
19. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ: Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 89:6998, 1992
20. Ross R, Masuda J, Raines EW: Cellular interactions, growth factors, and smooth muscle proliferation in atherogenesis. Ann NY Acad Sci 598:102, 1990
21. Hakkert BC, Rentenaar JM, van Mourik JA: Monocytes enhance the bidirectional release of type 1 plasminogen activator inhibitor by endothelial cells. Blood 76:2272, 1990
22. Tipping PG, Davenport P, Gallicchio M, Filonzi EL, Apostopoulos J, Wojta J: Atheromatous plaque macrophages produce plasminogen activator inhibitor type-1 and stimulate its production by endothelial cells and vascular smooth muscle cells. Am J Pathol 143:875, 1993
23. Schleef RR, Loskutoff DJ: Fibrinolytic system of vascular endothelial cells - Role of plasminogen activator inhibitors. Haemostasis 18:328, 1988
24. Loskutoff DJ, Sawdey M, Mimuro J: Type 1 plasminogen activator inhibitor. Prog Hemost Thromb 9:87, 1989
25. Constantinides P, Harkey M: Electron microscopic exploration of human endothelium in step-serial sections of early and advanced atherosclerotic lesions. Ann NY Acad Sci 598:113, 1990
26. Hamsten A: Hemostatic function and coronary artery disease. N Engl J Med 332:677, 1995
27. Handt S, Jerome WG, Braaten JV, Lewis JC, Kirkpatrick CJ, Hantgan RR: PAI-1 released from cultured human endothelial cells delays fibrinolysis and is incorporated into the developing fibrin clot. Fibrinolysis 8:104, 1994
28. Nielsen LS, Andreasen PA, Grondahl-Hansen J, Huang J-Y, Kristensen P, Dano K: Monoclonal antibodies to human 54000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells - Inhibitor neutralization and one step affinity purification. Thromb Haemost 55:206, 1986
29. Jaffe EA, Nachman RL, Becker CG, Minick CR: Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 52:2745, 1973
30. Carr ME, Shen LL, Hermans J: Mass-length ratio of fibrin fibers from gel permeation and light scattering. Biopolymers 16:1, 1977
31. Blomback B, Okada M: On pores in fibrin gels. Thromb Res 26:141, 1982
32. Nair CH, Azhar A, Dhall DP: Studies on fibrin network structure in human plasma. Part One: Methods for clinical application. Thromb Res 64:455, 1991
33. Carr ME, Hermans J: Size and density of fibrin fibers from turbidity. Macromolecules 11:46, 1978
34. Blomback B, Carlsson K, Hessel B, Liljeborg A, Procyk R, Aslund N: Native fibrin gel networks observed by 3D microscopy, permeation and turbidity. Biochim Biophys Acta 997:96, 1989
35. Wu JH, Siddiqui K, Diamond SL: Transport phenomena and clot dissolving therapy: An experimental investigation of diffusion controlled and permeation-enhanced fibrinolysis. Thromb Haemost 72:105, 1994
36. Blinc A, Kennedy SD, Bryant RG, Marder VJ, Francis CW: Flow through clots determines the rate and pattern of fibrinolysis. Thromb Haemost 71:230, 1993
37. Diamond SL, Anand S: Inner clot diffusion and permeation during fibrinolysis. Biophys J 65:2622, 1993
38. Shah GA, Nair CH, Dhall DP: Comparison of fibrin networks in plasma and fibrinogen solution. Thromb Res 45:257, 1987
39. Hantgan RR, Hermans J: Assembly of fibrin. A light scattering study. J Biol Chem 254:11272, 1979
40. Braaten J, Jerome WG, Hantgan RR: Uncoupling fibrin from integrin receptors hastens fibrinolysis at the platelet-fibrin interface. Blood 83:982, 1994
41. Dodam JR, Olson NC, Friedman M: Differential effects of tumor necrosis factor-α and platelet-activating factor on bovine pulmonary artery endothelial cells in vitro. Exp Lung Res 20:131, 1994
42. Mauerhoff T, Belfiore A, Pujol-Borrell R, Bottazzo GF: Growth inhibition of human endothelial cells by human recombinant tumor necrosis factor-α and interferon-γ. Tumori 80:301, 1994
43. Schroder H: Defibrotide protects endothelial cells, but not L929 tumor cells, from tumor necrosis factor-α-mediated cytotoxicity. J Pharm Pharmacol 47:250, 1995
44. van de Wiel P, Weitenberg E, van der Pijl A, Bloksma N: Factors that define the susceptibility of endothelial cells to tumor necrosis factor and lipid A. Immunopharmacology 23:49, 1992
45. Madison EL, Goldsmith EJ, Gerard RD, Gething M-J, Sambrook JF: Serpin-resistant mutants of tissue-type plasminogen activator. Nature 339:721, 1989
46. Madison EL, Goldsmith EJ, Gerard RD, Gething M-J, Sambrook JF, Bassel-Duby RS: Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1. Proc Natl Acad Sci USA 87:3530, 1990
47. Bennett WF, Paoni NF, Keyt BA, Botstein D, Jones AJS, Presta L, Wurn FM, Zoller MJ: High resolution analysis of functional determinants on human tissue-type plasminogen activator. J Biol Chem 266:5191, 1991
48. Cantor CR, Schimmel PR (eds): Size and shape of macromolecules, in Biophysical Chemistry. Part II: Techniques for the Study of Biological Structure and Function. San Francisco, CA, W.H. Freeman, 1980, p 539
49. Mottonen J, Strand A, Symersky J, Sweet RM, Danley DE, Geoghegan KF, Gerard RD, Goldsmith EI: Structural basis of latency in plasminogen activator inhibitor 1. Nature 355:270, 1992
50. Stewart UA, Bradley MS, Johnson CS Jr, Gabriel DA: Transport of probe molecules through fibrin gels as observed by means of holographic relaxation methods. Biopolymers 27:173, 1988
51. Keijer J, Linders M, Van Zonneveld AJ, Ehrlich HJ, De Boer JP, Pannekoek H: The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: Localization of interaction sites and physiologic relevance. Blood 78:401, 1991
52. Wagner OF, de Vries C, Hohmann C, Veerman H, Pannekoek H: Interaction between plasminogen activator inhibitor 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). J Clin Invest 84:647, 1989
53. Anderson HV, Willerson JT: Thrombolysis in acute myocardial infarction. N Engl J Med 329:703, 1993
54. International Symposium: Update in thrombolysis 1994. Vienna, Austria, September 1994. Ann Hematol 69:S64, 1994
55. Hantgan RR, Nichols WL, Ruggieri ZM: von Willebrand factor competes with fibrin for occupancy of GPIIb:IIIa on thrombin-stimulated platelets. Blood 75:889, 1990
56. Lang IM, Marsh JJ, Olman MA, Moser KM, Loskutofff DJ, Schleef RR: Expression of type 1 plasminogen activator inhibitor in chronic pulmonary thromboemboli. Circulation 89:2715, 1994
57. Loskutoff DJ, Sawdey M, Keeton, Schneiderman J, Lan I, Schleef R: Analysis of PAI-1 gene expression in vivo using in situ hybridization. Ann NY Acad Sci 714:259, 1994
58. Colucci M, Paramo JA, Collen D: Inhibition of one-chain and two-chain forms of human tissue-type plasminogen activator by the fast-acting inhibitor of plasminogen activator in vitro and in vivo. J Lab Clin Med 108:53, 1986
59. Fassina G, Chaiken IM: Analytical high-performance affinity chromatography. Adv Chromatogr 27:247, 1987